Glenn J. Jaffe
About
In The Last Decade
Glenn J. Jaffe
293 papers receiving 16.3k citations
Hit Papers
Peers
Comparison fields: 5 of 146
- Ophthalmology 14.3k
- Radiology, Nuclear Medicine and Imaging 8.6k
- Molecular Biology 3.1k
- Epidemiology 999
- Rheumatology 987
Countries citing papers authored by Glenn J. Jaffe
This map shows the geographic impact of Glenn J. Jaffe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Glenn J. Jaffe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Glenn J. Jaffe more than expected).
Fields of papers citing papers by Glenn J. Jaffe
This network shows the impact of papers produced by Glenn J. Jaffe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Glenn J. Jaffe. The network helps show where Glenn J. Jaffe may publish in the future.
Co-authorship network of co-authors of Glenn J. Jaffe
This figure shows the co-authorship network connecting the top 25 collaborators of Glenn J. Jaffe. A scholar is included among the top collaborators of Glenn J. Jaffe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Glenn J. Jaffe. Glenn J. Jaffe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 3 | |
| 3 | 4 | |
| 4 | 2 | |
| 5 | Safety and Efficacy of Risuteganib in Intermediate Non-exudative Age-Related Macular Degeneration | 3 |
| 6 | Imaging Features Associated with Progression to Geographic Atrophy in Age-Related Macular Degeneration: CAM Report 5. | 6 |
| 7 | Meta-learning approach to automatically register multivendor retinal images | 2 |
| 8 | 70 | |
| 9 | 165 | |
| 10 | Resolution of Retinal Fluid on Optical Coherence Tomography in the Comparison of AMD Treatments Trials (CATT) | 3 |
| 11 | Retinal Angiomatous Proliferation and Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) | 1 |
| 12 | Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) | 1 |
| 13 | 22 | |
| 14 | Reproducibility of Optical Coherence Tomography Image Grading During the Comparisons of Age-Related Macular Degeneration Treatments Trials (CATT) | 7 |
| 15 | Comparison of RC and Investigator Determined Retinal and Subretinal fluid in the Comparison of Age-Related Macular Degeneration Treatment Trials (CATT) | 1 |
| 16 | Baseline Predictors of Visual Acuity Response to Ranibizumab and Bevacizumab in the Comparison of AMD Treatment Trial (CATT) | 3 |
| 17 | A Phase 2 Study of Encapsulated CNTF-Secreting Cell Implant (NT-501) In Patients with Geographic Atrophy Associated with Dry AMD | 3 |
| 18 | Complement-mediated Injury in Cultured Human RPE Cells | 1 |
| 19 | Safety and Drug Release Profile of Injectable Intravitreal Sustained–Release Fluocinolone Acetonide Device | 2 |
| 20 | Fluocinolone Acetonide Intravitreal Implant for Uveitis Affecting the Posterior Segment of the Eye | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.